Drugs / RASEGLURANT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00820105 | Dec 2008 → Jan 2010 | migraine disorder | Addex Pharma S.A. | Terminated | No outcome recorded |
| Phase 2 | NCT00810485 | Dec 2008 → Dec 2009 | gastroesophageal reflux disease | Addex Pharma S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00820079 | Dec 2008 → Oct 2009 | gastroesophageal reflux disease | Addex Pharma S.A. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2009-12-15 | Addex Pharma S.A. | Results Development of ADX10059 Ended for Long-term Use addextherapeutics.com ↗
Addex Pharmaceuticals (SIX:ADXN) announced today that based on preliminary review of the unblinded data from study 206, it has terminated development of ADX10059 for chronic indications, including long term treatment of gastroesophageal reflux disease and migraine prophylaxis. |
| 2009-12-14 | Addex Pharma S.A. | Results Addex Ends Migraine Prevention Study addextherapeutics.com ↗
Addex Pharmaceuticals (SIX:ADXN) announced today that it has decided to end prematurely the migraine prevention study 206. |
| 2009-11-16 | Addex Pharma S.A. | Results Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial addextherapeutics.com ↗
Addex Pharmaceuticals (SWX:ADXN), the allosteric modulation company, announced that it achieved statistically significant efficacy on the primary endpoint, increasing the number of symptom free days in the Phase IIb trial of ADX10059 as a monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. |
| 2009-11-03 | Addex Pharma S.A. | Results Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference addextherapeutics.com ↗ |
| 2009-09-14 | Addex Pharma S.A. | Results Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID) addextherapeutics.com ↗
In a recently completed study using the “MPTP” primate model, all doses of ADX10059 abolished levodopa induced dyskinesia in the first hour after levodopa administration. |
| 2009-05-27 | Addex Pharma S.A. | Results Glutamate Receptor “mGluR5” Implicated in GERD addextherapeutics.com ↗
The researchers also found that night time reflux, which causes sleep disturbance and increased risk of esophageal damage, and reflux events following meals were also significantly reduced by ADX10059 therapy. |
| 2009-04-29 | Addex Pharma S.A. | Results Addex Presents Data on ADX10059 at the AAN addextherapeutics.com ↗
data suggests glutamate receptor “mglur5” is clinically relevant for migraine |
| 2008-09-10 | Addex Pharma S.A. | Results Better Tolerated Formulation of ADX10059 Reduces Acid Reflux addextherapeutics.com ↗
Addex Pharmaceuticals (SWX:ADXN) announced clinical data showing that the modified release formulation of ADX10059 has improved commercial potential. |
| 2008-01-03 | Addex Pharma S.A. | Results Addex Announces ADX10059 Phase IIa Acute Anxiety Data addextherapeutics.com ↗
Addex Pharmaceuticals (SWX: ADXN) announced today that ADX10059 did not reduce acute anticipatory anxiety in a small Phase IIa study in patients with dental anxiety. |
| 2007-10-29 | Addex Pharma S.A. | Results Addex Presents ADX10059 GERD Data at Conference addextherapeutics.com ↗
New data released today for the first time show that ADX10059 controlled stomach acid reflux during the critical period following meals, when GERD can be most troublesome. |
| 2007-04-20 | Addex Pharma S.A. | Results Addex reports positive results in Phase IIa clinical trial with ADX10059 in Migraine addextherapeutics.com ↗
The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and improvement of migraine pain at other time points. |
| 2007-04-17 | Addex Pharma S.A. | Results Addex achieves statistically significant outcome in Phase IIa clinical trial with ADX10059 in Gastro-Esophageal Reflux Disease addextherapeutics.com ↗
The study achieved its primary objective, the control of 24-hour esophageal pH, with statistical significance, and also showed statistically significant improvements in many of the secondary measures, including clinical symptoms of GERD. |
All press releases naming this drug 20 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RASEGLURANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545036 ↗ |
| Known as | ADX10059 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00820105 ↗ |
| Action | Inhibit | “mGluR5 Negative Allosteric Modulator ADX10059” NCT00810485 ↗ |
| Modality | Small molecule | — CHEMBL3545036 ↗ |
| Route | Oral | “oral administration” NCT00820079 ↗ |
| Target | GRM5 | “mGluR5 Negative Allosteric Modulator ADX10059” NCT00810485 ↗ |